Dr. Leena Niemistö starts as new Chair of the Board of Nexstim Plc

Press Release, Helsinki, 11 November 2019 at 12.20 pm (EET)Dr. Leena Niemistö starts as new Chair of the Board of Nexstim PlcNexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or “Company”) announces that the Extraordinary General Meeting of Shareholders has elected Leena Niemistö as the new Chair of the Board of Directors.Niemistö has distinguished experience in the field of health care and corporate management. She holds an MD and a PhD from the University of Helsinki and has specialised in physical and rehabilitation medicine, the field where she worked as a clinician for more than twenty years. In addition, she has worked as a CEO in a private healthcare company Dextra and as a deputy CEO in the social and healthcare company Pihlajalinna.Currently Niemistö is a board member of four publicly listed companies in Finland. She is also an active investor in health-tech growth companies. Niemistö’s investment company is the largest shareholder of Nexstim.Leena Niemistö commented: “I’m truly enthusiastic to start working with this highly professional team of Nexstim. My personal mission is to help Finnish health-tech companies to develop precise and cost-effective diagnostic and treatment methods for patients suffering from chronic disorders. Nexstim has potential to improve significantly the quality of life of patients with major depression and chronic neuropathic pain.”  Niemistö has been recognised with several acknowledgements, such as the Business Angel of the year 2016, the Top 2 Influencer of Healthcare sector 2015 in Finland, Veuve Clicquot Business Woman 2009, the Top 2 to 3 Female Businessinfluencer in Finland in years 2017-2019 and the Winner of the Women’s Board Award 2019.The Extraordinary General Meeting of Shareholders elected also Martin Forss, M.Sc (econ), as a new member of the board. Forss is an entrepreneur, investor and board professional in small and mid-sized companies. He is also known as experienced service business executive: His latest operative responsibility was as CEO of the private dentistry company Oral Hammaslääkärit, the market leader in Finland.Martin Jamieson will continue as CEO of Nexstim and as a board member of the company.Martin Jamieson commented: “I am delighted that Leena Niemistö, who has a long experience both in the field of health care and business management, will take the position of the Chair. The whole company is looking forward to working with these two new renowned board members in capitalising the significant potential of the company’s SmartFocus® TMS technology.”Further information is available on the website www.nexstim.com, or by contacting:Martin Jamieson, CEO
+44 771 516 3942
About Nexstim PlcNexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.For more information please visit www.nexstim.com
AttachmentNexstim_Press Release_Leena Niemistö_EN_FINAL

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.